Internationale PatientenAktuellesKontakt
UNIVERSITÄTSKLINIKENHACETTEPE
Termin
DE
  1. Home
  2. Ärzte
  3. Prof. Dr. Hakan Göker
Prof. Dr. Hakan Göker

Prof. Dr.

Hakan Göker

Hematology · Erwachsenenklinik

Termin vereinbaren

This page is not yet available in Deutsch. The Turkish version is shown below.

Publications

Source: Hacettepe University academic database (AVESİS) · All publications (224) ↗

Articles 162

  1. Determinants of levofloxacin prophylaxis failure in high-risk haematology patients: a prospective study integrating resistant colonization and pharmacokinetic/pharmacodynamic target attainment—authors’ responseBOŞNAK C., METAN G., Zarakolu P., ALADAĞ KARAKULAK E., PINAR A., GÖKER H., et al.Journal of Antimicrobial Chemotherapy, cilt.81, sa.11, 2026 (SCI-Expanded, Scopus)
  2. Determinants of levofloxacin prophylaxis failure in high-risk haematology patients: a prospective study integrating resistant colonization and pharmacokinetic/pharmacodynamic target attainmentBOŞNAK C., METAN G., Zarakolu P., Karakulak E. A., PINAR A., GÖKER H., et al.Journal of Antimicrobial Chemotherapy, cilt.81, sa.9, 2026 (SCI-Expanded, Scopus)
  3. Direct Second Autologous Stem Cell Transplantation Versus Re-Induction Followed by Transplantation in Relapsed Multiple Myeloma: A Multicenter Real-World StudyKars T. U., GÖKER H., DEMİROĞLU H., MALKAN Ü. Y., ALADAĞ KARAKULAK E., Erdekli F. T., et al.Journal of Clinical Medicine, cilt.15, sa.13, 2026 (SCI-Expanded, Scopus)
  4. Anemia in the patients with acute myeloid leukemia revisited: Prognostic importance of anemia on treatment-naïve patientsÇınar O. E., Malkan U. Y., Aladag E., Demiroglu H., Büyükaşık Y., Göker H., et al.Acta Medica, cilt.56, sa.2, ss.116-121, 2025 (TRDizin)
  5. Turkish translation, validity, and reliability of the European organization for research and treatment of cancer quality of life-high dose chemotherapy29 in patients undergone hematopoietic stem cell transplantationKabak V. Y., Karahan S., Aladag E., Duger T., Uysal S. A., Erdem F. I., et al.Turkish Journal of Medical Sciences, cilt.55, sa.3, ss.540-546, 2025 (SCI-Expanded, Scopus, TRDizin)
  6. Long-Term Outcomes of Allogeneic Stem Cell Transplantation for Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma: Multi-center Experience from TurkeyUysal A., SOYER N., Ozdogu H., GÖKER H., ÇINAR O. E., Deveci B., et al.INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, cilt.41, sa.1, ss.43-52, 2025 (SCI-Expanded, Scopus)
  7. DOES THE PRESENCE OF ANEMIA HAVE AN IMPACT ON PHYSICAL FUNCTIONS IN PATIENTS TREATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION?YILDIZ KABAK V., ATASAVUN UYSAL S., ALADAĞ KARAKULAK E., GÖKER H., DÜGER T.TURKISH JOURNAL OF PHYSIOTHERAPY REHABILITATION-TURK FIZYOTERAPI VE REHABILITASYON DERGISI, cilt.35, sa.3, ss.290-296, 2024 (ESCI, Scopus, TRDizin)
  8. Exploring the distribution and prognostic effect of the ABO blood types of COVID-19 patients during delta and omicron waves: A case control studyGÖKER H., ÇINAR O. E., ISMAYILOV R., Özdemir E., MALKAN Ü. Y., ALADAĞ E., et al.Acta Medica, cilt.54, sa.2, ss.97-102, 2023 (Hakemli Dergi)
  9. Asymptomatic unilateral phrenic nerve palsy after bortezomib treatment in a newly diagnosed multiple myeloma patientCoskunpinar M., Erdogdu B., GÖKER H.JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.29, sa.2, ss.502-505, 2023 (SCI-Expanded, Scopus)
  10. Hypophosphatemia related to the use of ibrutinibKARADENİZ M., ÇINAR O. E., Erdogdu B., MALKAN Ü. Y., GÖKER H., ÖZCEBE O. İ.Journal of Oncology Pharmacy Practice, 2023 (SCI-Expanded, Scopus)
  11. A single-center experience of haploidentical stem cell transplantation in hematological malignanciesMALKAN Ü. Y., GÖKER H., DEMİROĞLU H., Tekin F., Akdemir B., ALADAĞ KARAKULAK E., et al.Turkish Journal of Medical Sciences, cilt.53, sa.1, ss.352-359, 2023 (SCI-Expanded, Scopus, TRDizin)
  12. Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874ÇINAR O. E., Erdogdu B., KARADENİZ M., ÜNAL S., MALKAN Ü. Y., GÖKER H., et al.MEDICINA-LITHUANIA, cilt.58, sa.11, 2022 (SCI-Expanded, Scopus)
  13. Validity and reliability of the Turkish version of the functional assessment of cancer therapy-bone marrow transplant (FACT-BMT) quality of life questionnaire in patients undergoing bone marrow transplantationYILDIZ KABAK V., Demircioglu A., Aladag E., KARAHAN S., GÖKER H., ATASAVUN UYSAL S., et al.Palliative and Supportive Care, cilt.20, sa.4, ss.556-563, 2022 (SSCI, Scopus)
  14. Hepatitis E Virus Prevalence and Associated Risk Factors in High-Risk Groups: A Cross-Sectional StudyBALABAN H. Y., ASLAN A. T., AKDOĞAN KITTANA F. N., ALP A., DAĞ O., AYAR Ş. N., et al.TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.33, sa.7, ss.615-624, 2022 (SCI-Expanded, Scopus, TRDizin)
  15. Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 studyAkpinar S., Tekgunduz E., Esen R., YILMAZ M., Karakus V., VURAL F., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.61, sa.1, 2022 (SCI-Expanded, Scopus)
  16. Covid-19 Related Fatality and Risk Factors in Multiple Myeloma: A Multicenter Cohort StudyKARADENİZ M., GÖKER H., Aydin O., Turgut M., MALKAN Ü. Y., Sener E., et al.UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.32, sa.4, ss.209-213, 2022 (SCI-Expanded, Scopus, TRDizin)
  17. Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 VaccineErdogdu B., ÇINAR O. E., Malkan Ü. Y., AKSU S., DEMİROĞLU H., BÜYÜKAŞIK Y., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.32, sa.1, ss.65-67, 2022 (SCI-Expanded, Scopus, TRDizin)
  18. Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantationKARATAŞ A., GÖKER H., DEMİROĞLU H., MALKAN Ü. Y., Velet M., ÇINAR O. E., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.2, ss.413-419, 2022 (SCI-Expanded, Scopus, TRDizin)
  19. Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemiaALADAĞ KARAKULAK E., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.60, sa.2, 2021 (SCI-Expanded, Scopus)
  20. Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase InhibitorsKARAKULAK U. N., ALADAĞ KARAKULAK E., HEKİMSOY V., ŞAHİNER M. L., KAYA E. B., ÖZER N., et al.CARDIOVASCULAR TOXICOLOGY, cilt.21, sa.3, ss.216-223, 2021 (SCI-Expanded, Scopus)
  21. Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Munster Chemotherapy in Adult Acute Lymphoblastic LeukemiaALADAĞ KARAKULAK E., Aktimur S. H., Aydin O., DEMİROĞLU H., BÜYÜKAŞIK Y., AKSU S., et al.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.21, sa.3, ss.147-153, 2021 (SCI-Expanded, Scopus)
  22. Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell TransplantationCiftciler R., GÖKER H., DEMİROĞLU H., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.38, sa.1, ss.33-40, 2021 (SCI-Expanded, Scopus, TRDizin)
  23. Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin LymphomaDEMİROĞLU H., Ciftciler R., BÜYÜKAŞIK Y., GÖKER H.TURKISH JOURNAL OF HEMATOLOGY, cilt.38, sa.3, ss.204-210, 2021 (SCI-Expanded, Scopus, TRDizin)
  24. Effect of Salvage Chemotherapy Before Donor Lymphocyte Infusion in Patients With Relapse After Allogeneic Hematologic Stem Cell TransplantationALADAĞ KARAKULAK E., GÖKER H., BÜYÜKAŞIK Y., DEMİROĞLU H.TRANSPLANTATION PROCEEDINGS, cilt.53, sa.1, ss.391-395, 2021 (SCI-Expanded, Scopus)
  25. Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish ExperienceYilmaz F., SOYER N., Seval G. C., Bozdag S. C., TOPÇUOĞLU P., ÜNAL A., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.38, sa.3, ss.195-203, 2021 (SCI-Expanded, Scopus, TRDizin)
  26. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantationALADAĞ KARAKULAK E., DEMİROĞLU H., Malkan Ü. Y., Akman U., GÖKER H., BÜYÜKAŞIK Y.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.51, sa.1, ss.355-358, 2021 (SCI-Expanded, Scopus, TRDizin)
  27. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort StudyALADAĞ KARAKULAK E., DEMİROĞLU H., BÜYÜKAŞIK Y., GÖKER H.TURKISH JOURNAL OF HEMATOLOGY, cilt.38, sa.2, ss.138-144, 2021 (SCI-Expanded, Scopus, TRDizin)
  28. Comparison of single and double autologous stem cell transplantation in multiple myeloma patientsMalkan Ü. Y., DEMİROĞLU H., BÜYÜKAŞIK Y., KARATAŞ A., ALADAĞ KARAKULAK E., GÖKER H.OPEN MEDICINE, cilt.16, sa.1, ss.192-197, 2021 (SCI-Expanded, Scopus)
  29. Central nervous system involvement in patients with acute myeloid leukemiaYAŞAR H. A., ÇINAR O. E., Koylu N. Y., BARIŞTA İ., GÖKER H., BÜYÜKAŞIK Y.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.51, sa.5, ss.2351-2356, 2021 (SCI-Expanded, Scopus, TRDizin)
  30. Effects of partly supervised and home-based exercise program in patients undergoing hematopoietic stem cell transplantation: a case-control studyYILDIZ KABAK V., GÖKER H., DÜGER T.SUPPORTIVE CARE IN CANCER, cilt.28, sa.12, ss.5851-5860, 2020 (SCI-Expanded, Scopus)
  31. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasmaKARATAŞ A., İNKAYA A. Ç., DEMİROĞLU H., AKSU S., Haziyev T., ÇINAR O. E., et al.Transfusion and Apheresis Science, cilt.59, sa.5, 2020 (SCI-Expanded, Scopus)
  32. Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory MyelomaBEKSAÇ M., Aydin Y., GÖKER H., Turgut M., Besisik S. K., Cagirgan S., et al.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.20, sa.8, 2020 (SCI-Expanded, Scopus)
  33. Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: A retrospective multicenter study of Turkish hematology research and education group (ThREG)SOYER N., Gunduz M., Tekgunduz E., Deveci B., Ozdogu H., ŞAHİN H. H., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.59, sa.4, 2020 (SCI-Expanded, Scopus)
  34. Cardiac adverse events during stem cell transplantation for hematological malignancies: A single centre experienceALADAĞ KARAKULAK E., DEMİROĞLU H., BÜYÜKAŞIK Y., KARAKULAK U. N., Tekin F., AKSU S., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.59, sa.2, 2020 (SCI-Expanded, Scopus)
  35. Richter's transformation in patients with chronic lymphocytic leukemia: a cohort study about risk factorsOKAY M., GÜNEŞ G., Malkan Ü. Y., Heziyev T., GÖKER H., HAZNEDAROĞLU İ. C., et al.LEUKEMIA & LYMPHOMA, cilt.61, ss.50-52, 2020 (SCI-Expanded, Scopus)
  36. Predictive factors for stem cell mobilization failure in multiple myeloma patients: A single center experienceGÖKER H., Ciftciler R., DEMİROĞLU H., Turgut M., SAYINALP N., Haznedaroglu I. C., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.59, sa.1, 2020 (SCI-Expanded, Scopus)
  37. The experience of allogeneic hematopoietic stem cell transplantation in a patient with X-linked adrenoleukodystrophyCiftciler R., GÖKER H., BÜYÜKAŞIK Y., TOPÇU M., Gevher N., DEMİROĞLU H.TRANSFUSION AND APHERESIS SCIENCE, cilt.59, sa.1, 2020 (SCI-Expanded, Scopus)
  38. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experienceOzbalak M., SALİHOĞLU A., Soysal T., Karadogan I., PAYDAŞ S., Ozdemir E., et al.ANNALS OF HEMATOLOGY, cilt.99, sa.2, ss.301-307, 2020 (SCI-Expanded, Scopus)
  39. Impact of ABO blood group incompatibility on the outcomes of allogeneic hematopoietic stem cell transplantationCiftciler R., GÖKER H., BÜYÜKAŞIK Y., KARAAĞAÇ AKYOL T., AKSU S., Tekin F., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.59, sa.1, 2020 (SCI-Expanded, Scopus)
  40. Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at DiagnosisCiftciler R., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.37, sa.4, ss.256-262, 2020 (SCI-Expanded, Scopus, TRDizin)
  41. The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid LeukemiaCiftciler R., HAZNEDAROĞLU İ. C., SAYINALP N., Ozcebe O., AKSU S., DEMİROĞLU H., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.37, sa.2, ss.116-120, 2020 (SCI-Expanded, Scopus, TRDizin)
  42. The comparison of bone marrow kinetics between patients with acute myeloid leukemia and acute promyelocytic leukemia after induction chemotherapyCiftciler R., HAZNEDAROĞLU İ. C., Ozcebe O., AKSU S., SAYINALP N., GÖKER H., et al.IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, cilt.42, sa.1, ss.17-21, 2020 (SCI-Expanded, Scopus)
  43. Acute Graft-Versus-Host Disease: A Brief ReviewALADAĞ KARAKULAK E., KELKİTLİ E., GÖKER H.TURKISH JOURNAL OF HEMATOLOGY, cilt.37, sa.1, ss.1-4, 2020 (SCI-Expanded, Scopus, TRDizin)
  44. Comparison of bortezomib-cyclophosphamide-dexametha-sone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patientsCiftciler R., GÖKER H., BÜYÜKAŞIK Y., SAYINALP N., HAZNEDAROĞLU İ. C., AKSU S., et al.HEMATOLOGY REPORTS, cilt.12, sa.1, 2020 (ESCI, Scopus)
  45. What is the role of the decrease in immunoglobulin level after the first cycle in patient with multiple myeloma?GÖKER H., KELKİTLİ E., Turgut M.AMERICAN JOURNAL OF HEMATOLOGY, cilt.94, 2019 (SCI-Expanded, Scopus)
  46. SECONDARY MALIGNANCIES IN PATIENTS WITH MULTIPLE MYELOMAALADAĞ KARAKULAK E., BÜYÜKAŞIK Y., DEMİROĞLU H., AKSU S., GÖKER H.AMERICAN JOURNAL OF HEMATOLOGY, cilt.94, 2019 (SCI-Expanded, Scopus)
  47. Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid LeukemiaCiftciler R., DEMİROĞLU H., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., Ozcebe O., et al.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, sa.11, ss.729-734, 2019 (SCI-Expanded, Scopus)
  48. Impact of Pre-transplant and Post-transplant Remission Status of Patients on Survival in Newly Diagnosed Multiple MyelomaCiftciler R., GÖKER H., BÜYÜKAŞIK Y., ALADAĞ KARAKULAK E., DEMİROĞLU H.INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, cilt.35, sa.4, ss.655-661, 2019 (SCI-Expanded, Scopus)
  49. Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From TurkeyBEKSAÇ M., Seval G. C., PAYDAŞ S., Tuglular T. F., ARSLAN Ö., GÖKER H., et al.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, sa.10, 2019 (SCI-Expanded, Scopus)
  50. Mantle cell lymphoma: a Turkish Multi-Center StudyOKAY M., MELETLİ Ö., KELKİTLİ E., Malkan Ü. Y., Turgut M., BÜYÜKAŞIK Y., et al.JOURNAL OF BUON, cilt.24, sa.5, ss.2084-2089, 2019 (SCI-Expanded, Scopus)
  51. DETERMINANTS OF CARDIORESPIRATORY FITNESS LEVEL IN HEMATOPOIETIC STEM CELL TRANSPLANTATION CANDIDATESYILDIZ KABAK V., GÖKER H., ATASAVUN UYSAL S., DEMİROĞLU H., ALADAĞ KARAKULAK E., OKAY M., et al.TURKISH JOURNAL OF PHYSIOTHERAPY REHABILITATION-TURK FIZYOTERAPI VE REHABILITASYON DERGISI, cilt.30, sa.2, ss.81-88, 2019 (ESCI, Scopus, TRDizin)
  52. Impact of bone marrow plasma cells percentage on survival at diagnosis and pre-transplant period in newly diagnosed multiple myeloma: Experience of a single center from TurkeyCiftciler R., GÖKER H., BÜYÜKAŞIK Y., ALADAĞ KARAKULAK E., Saglam E. A., DEMİROĞLU H.TRANSFUSION AND APHERESIS SCIENCE, cilt.58, sa.3, ss.313-317, 2019 (SCI-Expanded, Scopus)
  53. Extramedullary relapses of acute leukemias after allogeneic hematopoietic stem cell transplantation: clinical features, cumulative incidence, and risk factorsGunes G., GÖKER H., DEMİROĞLU H., Malkan Ü. Y., BÜYÜKAŞIK Y.BONE MARROW TRANSPLANTATION, cilt.54, sa.4, ss.595-600, 2019 (SCI-Expanded, Scopus)
  54. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid LeukemiaCiftciler R., DEMİROĞLU H., BÜYÜKAŞIK Y., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., et al.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, sa.3, ss.177-182, 2019 (SCI-Expanded, Scopus)
  55. Impact of pre-transplant bone marrow blast percentage on survival in acute myeloid leukemia patientsCiftciler R., GÖKER H., BÜYÜKAŞIK Y., Malkan Ü. Y., Saglam E. A., DEMİROĞLU H.INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, cilt.12, sa.7, ss.9288-9294, 2019 (SCI-Expanded)
  56. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort StudyCiftciler R., GÖKER H., DEMİROĞLU H., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.36, sa.2, ss.88-96, 2019 (SCI-Expanded, Scopus, TRDizin)
  57. Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiencyALADAĞ KARAKULAK E., AKSU S., DEMİROĞLU H., SAYINALP N., GÖKER H., HAZNEDAROĞLU İ. C., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.5, ss.1560-1563, 2019 (SCI-Expanded, Scopus, TRDizin)
  58. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphomaOKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., Malkan Ü. Y., Ciftciler R., ALADAĞ KARAKULAK E., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.4, ss.985-992, 2019 (SCI-Expanded, Scopus, TRDizin)
  59. Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patientsCIFTCILER R., DEMİROĞLU H., BÜYÜKAŞIK Y., OKAY M., AKSU S., Sayinalp N., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.57, sa.6, ss.752-755, 2018 (SCI-Expanded, Scopus)
  60. Evaluation of Secondary Malignancies in Chronic Lymphocytic LeukemiaDEMİROĞLU H., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., et al.Journal of Global Oncology, ss.205, 2018 (ESCI)

All 162 on AVESİS →

Conference papers 61

  1. Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic transplantation: Retrospective multicenter study of Turkish hematology research and education group (THREG), updated dataSOYER N., Gunduz M., Tekgunduz E., Deveci B., Ozdogu H., ŞAHİN H. H., et al.45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.254-255, (Özet Bildiri)
  2. AZACYTIDINE BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION IS INFERIOR TO HD/ARA-C WITHRESPECT TO RELAPSE FOLLOWING TRANSPLANTATIONDEMİROĞLU H., OKAY M., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., GÜL Ö., BÜYÜKAŞIK Y., et al.24th EHA Congress, 13 - 16 Haziran 2019, cilt.3, ss.941-942, (Özet Bildiri)
  3. THE EVALUATION OF THE CLINICOPATHOLOGIC CHARACTERISTICS OF T-CELL NON-HODGKIN’S LYMPHOMA: THE SINGLE CENTER EXPERIENCESAYINALP N., ALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., AKSU S., DEMİROĞLU H., et al.15th International Conference on Malignant Lymphoma, İsviçre, 18 - 22 Haziran 2019, cilt.37, ss.366, (Özet Bildiri)
  4. HEMATOLOJİK MALİGNİTELERDE DONÖR LENFOSİT İNFÜZYONU ÖNCESİ VERİLEN KEMOTERAPİ SİKLUS SAYISININ SAĞKALIMA ETKİSİALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., BÜYÜKAŞIK Y., GÖKER H., DEMİROĞLU H.4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Nisan 2019, (Özet Bildiri)
  5. ASEMPTOMATİK D-DİMER YÜKSEKLİĞİ İMMÜNMONULATUAR KULLANAN MULTİPLE MYELOMADA TROMBOZU TAHMİN EDER Mİ: GERÇEK YAŞAM VERİSİAYDIN M. S., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., YAZGAN S. Ç., DEMİROĞLU H., ÖZCEBE O. İ., et al.4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Nisan 2019, (Özet Bildiri)
  6. MULTİPLE MYELOM HASTALARINDA İNDUKSİYON TEDAVİ SÜRESİNİN SAĞKALIMA ETKİSİALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., et al.3. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Türkiye, 8 - 09 Mart 2019, (Özet Bildiri)
  7. Long-Term Results of Non-Fludarabine Versus Fludarabine-Based Conditioning Regimens in Severe Aplastic Anemia PatientsALADAĞ KARAKULAK E., DEMİROĞLU H., Ciftciler R., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., et al.60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)
  8. Analysis of Elderly Patients with Chronic Myeloid LeukemiaKELKİTLİ E., GÖKER H., Turgut M., ATAY M. H.60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)
  9. AĞIR APLASTİK ANEMİ HASTALARINDA HEMATOPOETİK KÖK HÜCRE NAKLİNDE KULLANILAN HAZIRLIK REJİMLERİNİN KARŞILAŞTIRILMASIALADAĞ KARAKULAK E., DEMİROĞLU H., ÇİFTÇİLER R., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., et al.44.ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.261, (Özet Bildiri)
  10. PHİLADELPHİA KROMOZOMU POZİTİF AKUT MYELOİDLÖSEMİLİ OLGUÇİFTÇİLER R., ALADAĞ KARAKULAK E., OKAY M., GÖKER H., DEMİROĞLU H., BÜYÜKAŞIK Y.44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.340, (Özet Bildiri)
  11. MRG’DE TESADÜFEN SAPTANAN KEMİK İLİĞİNİN DİFFÜZ SİNYAL DEĞİŞİKLİKLERİ LENFOHEMATOPOETİK HASTALIKLARI ÖNGÖREBİLİR Mİ?ÇİFTÇİLER R., ALADAĞ KARAKULAK E., AKSU S., SAYINALP N., DEMİROĞLU H., GÖKER H., et al.44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.266, (Özet Bildiri)
  12. LENALIDOMID İLE MYELOMDA OTOLOG NAKİL SONRASI İLK NÜKSDE TALİDOMİD VE BORTEZOMİBE KIYASLA DAHA İYİ İLERLEMESİZ SAĞKALIMDEMİROĞLU H., AKSU S., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., et al.TÜRK HEMATOLOJİ DERNEĞİ, Türkiye, 31 Ekim - 03 Kasım 2018, (Tam Metin Bildiri)
  13. T HÜCRELİ LENFOMA HASTALARININ KLİNİK ÖZELLİKLERİNİN DEĞERLENDİRİLMESİ: TANIDAN PROGNOZA TEK MERKEZ DENEYİMİDEMİROĞLU H., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., et al.TÜRK HEMATOLOJİ DERNEĞİ, Türkiye, 31 Ekim - 03 Kasım 2018, (Tam Metin Bildiri)
  14. PHILADELPHIA KROMOZOMU POZİTİF AKUT MYELOİD LÖSEMİLİ OLGUDEMİROĞLU H., GÖKER H., BÜYÜKAŞIK Y., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., OKAY M.TÜRK HEMATOLOJİ DERNEĞİ, Türkiye, 31 Ekim - 03 Kasım 2018, (Tam Metin Bildiri)
  15. BRENTIXUMAB VEDOTIN IN CD30 LYMPHOMAS: SINGLE CENTER EXPERIENCEDEMİROĞLU H., SAYINALP N., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., GÖKER H., et al.IX. INTERNATIONAL EHOC, 17 - 20 Ekim 2018, cilt.73, (Tam Metin Bildiri)
  16. Extramedullary relapse of the AML following allo-HSCT: a case reporÇİFTÇİLER R., ALADAĞ KARAKULAK E., OKAY M., GÖKER H.IX. International Eurasian Hematology-Oncology Congress, Türkiye, 17 - 20 Ekim 2018, cilt.71, ss.43, (Özet Bildiri)
  17. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphomaOKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., MALKAN Ü. Y., CIFTCILER R., Aladag E., et al.9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Türkiye, 17 - 20 Ekim 2018, cilt.73, (Özet Bildiri)
  18. AKUT MYELOİD LÖSEMİLİ BİR OLGULDA SİTOZİN ARABİNOZİD İLİŞKİLİ PULMONER TOKSİSİTEÇİFTÇİLER R., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C., AKSU S., DEMİROĞLU H., GÖKER H., et al.4.İLAÇ VE TEDAVİ KONGRESİ, Kıbrıs (Kktc), 19 - 23 Eylül 2018, ss.254, (Özet Bildiri)
  19. COMPARISON OF MYELOABLATIVE AND REDUCED-INTENSITY CONDITIONING REGIMENS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIAÇİFTÇİLER R., OKAY M., ALADAĞ KARAKULAK E., BÜYÜKAŞIK Y., GÖKER H., DEMİROĞLU H.EUROPEAN HEMATOLOGY ASSOCIATION, 14 - 17 Haziran 2018, (Tam Metin Bildiri)
  20. EFFECT OF THE INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTSALADAĞ KARAKULAK E., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., et al.The International Congress of BMT 2018, Busan, Güney Kore, 30 Ağustos - 01 Eylül 2018, (Özet Bildiri)
  21. DOES ASYMPTOMATIC D-DIMER ELEVATION PREDICT THROMBOSIS IN PATIENTS ON IMMUNOMODULATORY DRUGS IN MULTIPLE MYELOMA: REAL-LIFE DATAAYDIN M. S., YAZGAN S. Ç., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., KELKİTLİ E., TURGUT M., et al.23rd Congress of EHA, Stockholm, İsveç, 14 - 17 Haziran 2018, (Özet Bildiri)
  22. POST-TRANSPLANT EBSTEIN-BARR VIRAL LOAD MONITORING EXPERIENCE IN A HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTERAYDIN M. S., İNKAYA A. Ç., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., TURGUT M., GÖKER H., et al.23rd Congress of EHA, Stockholm, İsveç, 14 - 17 Haziran 2018, (Özet Bildiri)
  23. Posttransplant Ebstain-Barr viral load monitoring experience in a hematopoietic stem cell transplantation centerAYDIN M. S., Inkaya Çağkan a., ALADAĞ KARAKULAK E., çiftçiler R., TURGUT M., GÖKER H., et al.European Hematology Association, 14 - 17 Haziran 2018, (Özet Bildiri)
  24. The Novel Translocation Of T(121) In Multiple Myeloma With Complex KaryotypeOKAY M., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., GÖKER H.23rd Congress of EHA, Stockholm, İsveç, 14 - 17 Haziran 2018, (Özet Bildiri)
  25. Does Asymptomatic D-Dimer Elevation Predict Thrombosis in Patient on Immunomodulatory Drugs in Multiple Myeloma: Real-Life DataAYDIN M. S., YAZGAN S. C., ALADAĞ KARAKULAK E., Çiftçiler R., KELKİTLİ E., TURGUT M., et al.European Hemtology Association, 14 - 17 Haziran 2018, (Özet Bildiri)
  26. RISK FACTORS FOR EARLY MORTALITY IN MULTIPLE MYELOMA WITH DIFFERENT SURVIVAL TIME CUT-OFF POINTS: REAL-LIFE DATAAYDIN M. S., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., DEMİROĞLU H., GÖKER H., TURGUT M., et al.23rd Congress of EHA, Stockholm, İsveç, 14 - 17 Haziran 2018, (Özet Bildiri)
  27. ANJİMMUNOBLASTİK T HÜCRELİ LENFOMA, ÇOK YÜZLÜ LENFOMAOKAY M., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., HEZİYEV T., GÖKER H., BÜYÜKAŞIK Y.2. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Mayıs 2018, (Özet Bildiri)
  28. PLAZMA HÜCRELİ LÖSEMİ ŞEKLİNDE PREZENTE OLAN WALDENSTROM MAKROGOBULİNEMİSİÇİFTÇİLER R., OKAY M., ALADAĞ KARAKULAK E., HEZİYEV T., AKSU S., SAYINALP N., et al.2. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Mayıs 2018, (Özet Bildiri)
  29. Common medical problems in adult patients with Hemophilia A: A single center experienceAYDIN M. S., OKAY M., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., DEMİROĞLU H., GÖKER H., et al.15. INTERNATIONAL HEMOPHILIA CONGRESS OF TURKEY, İstanbul, Türkiye, 4 - 07 Nisan 2018, (Özet Bildiri)
  30. DAMAK TUTULUMU İLE EKSTRAMEDÜLLER NÜKS OLAN RELAPS REFRAKTER MULTİPLE MYELOM OLGUSUÇİFTÇİLER R., OKAY M., ALADAĞ KARAKULAK E., DEMİROĞLU H., GÖKER H.3. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Kıbrıs (Kktc), 29 - 31 Mart 2018, (Özet Bildiri)
  31. EFFECT OF INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTSDEMİROĞLU H., ALADAĞ KARAKULAK E., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., et al.INTERNATIONAL CONGRESS OF BMT 2018, Busan, Güney Kore, 30 Ağustos - 01 Eylül 2018, cilt.53, (Tam Metin Bildiri)
  32. Prognosis of Multiple Myeloma in Younger Patients Who Are Undergoing Upfront Autologuous Stem Cell TransplantationKELKİTLİ E., GÖKER H., DEMİROĞLU H., TURGUT M., OKAY M., SAYINALP N., et al.LYMPHOMA AND MYELOMA 2017, New York, Amerika Birleşik Devletleri, 26 - 28 Kasım 2017, cilt.1, ss.43-44, (Özet Bildiri)
  33. Donor Lymphocyte Infusions: Single Center ExperienceKELKİTLİ E., GÖKER H., TURGUT M., DEMİROĞLU H., SAYINALP N., AKSU S., et al.LYMPHOMAMYELOMA 2017, New York, Amerika Birleşik Devletleri, 26 - 28 Kasım 2017, cilt.1, ss.48, (Özet Bildiri)
  34. Prognosis of Multiple Myeloma in Younger Patients who Undergoing Upfront Autologous Stem Cell TransplantationKELKİTLİ E., GÖKER H., demiroglu H., TURGUT M., SAYINALP N., AKSU S., et al.LYMPHOMA MYELOMA 2017, 26 - 28 Ekim 2017, (Özet Bildiri)
  35. Donor Lymhocyte Infusion: Single Center ExperienceKELKİTLİ E., GÖKER H., TURGUT M., Demiroğlu H., SAYINALP N., AKSU S., et al.LYMHOMA MYELOMA 2017, 26 - 28 Ekim 2017, (Özet Bildiri)
  36. Kemoterapiye refrakter primer mediastinal granülositik sarkom hastasının allojeneik kök hücre transplantasyonu ile tedavisiETGÜL S., MALKAN Ü. Y., TURGUT M., DEMİROĞLU H., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., et al.2. Hematolojik Onkoloji Kongresi, Kıbrıs (Kktc), 16 - 19 Şubat 2017, (Özet Bildiri)
  37. Determination of chemoterapoetic drugsensitivity subgroups of acute leukemiaTürk S., Ghasemi M., malkan Ü. Y., ERİKÇİ A., GÖKER H., HAZNEDAROĞLU İ. C., et al.The FEBS Journal, 3 - 08 Eylül 2016, (Özet Bildiri)
  38. Determination of chemoterapoetic drug sensitivity subgroups of acute leukemiaTÜRK S., Ghasemi M., MALKAN Ü. Y., Erikci A., GÖKER H., SAYINALP N., et al.41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Türkiye, 3 - 08 Eylül 2016, cilt.283, ss.373-374, (Özet Bildiri)
  39. AN IGD MYELOMA CASE THAT IS RESISTANT TO CARFILZOMIBMalkan Ü. Y., GÜNEŞ G., ETGÜL S., HAZNEDAROĞLU İ. C., DEMİROĞLU H., GÖKER H.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
  40. A COMPOSITE LYMPHOMA CASEMalkan Ü. Y., GÜNEŞ G., Yayar O., DEMİROĞLU H., GÖKER H., HAZNEDAROĞLU İ. C.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
  41. SUCCESSFUL TREATMENT OF RESISTANT CHRONIC GRAFT VERSUS HOST DISEASE WITH EXTRACORPOREAL PHOTOPHERESIS IN A PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENT WHO HAS UNDERGONE ALLOGENEIC STEM CELL TRANSPLANTATIONMalkan Ü. Y., GÜNEŞ G., ELİAÇIK E., Yayar O., GÖKER H., ÖZCEBE O. İ.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
  42. A LATE-ONSET ACUTE GRAFT VERSUS HOST DISEASE CASE WHO IS RESISTANT TO BOTH TACROLIMUS AND CYCLOSPORINEMalkan Ü. Y., GÜNEŞ G., Aslan T., AKSU S., GÖKER H., HAZNEDAROĞLU İ. C.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
  43. GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CMLAKSU S., Aktimur S. H., Arica D. C., Atay H., Bektas O., BÜYÜKAŞIK Y., et al.20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.690, (Özet Bildiri)
  44. Extramedullary relapses after allogeneic stem cell transplantation for leukemia: Clinical characteristics, cumulative incidence and risk factorsGoker H., Gunes G., Demiroglu H., Malkan Ü. Y., Haznedaroglu I., Sayinalp N., et al.Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
  45. Prognostic Factors for Survival of Elderly Patients with Acute Myeloid Leukemia after Intensive Chemotherapy: Validation of 3 Popular Prognostic ModelsKoca E., Halacoglu A., Malkan Ü. Y., Arica D., Karakus S., GÖKER H., et al.56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri)
  46. Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo StudyAvcu F., Guner M., Misirci M., Elci P., Safali M., GÖKER H., et al.56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri)
  47. Lower Doses of Plerixafor Use Is Sufficient to Effectively Mobilize PBSC (Peripheral Blood Hematopoetic Stem Cells) When Compared to Standard AdministrationGÖKER H., ELİAÇIK E., Altuntas F., Tekgunduz E., ÖZDEMİR E., Isik A., et al.56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri)
  48. GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CMLAKSU S., AKTİMUR S., ARİCA D., ATAY M. H., BEKTAŞ Ö., BÜYÜKAŞIK Y., et al.20th Congress of the European Hematology Association Vienna, Austria June 11-14, 2015, 11 - 14 Haziran 2014, (Tam Metin Bildiri)
  49. High-dose chemotherapy and autologons peripheral blood stein tell (PBSC) transplantation with initt-cryopreserved PBSCs in multiple myelomaGoker H., Eliacik E., Buyukasik Y., Haznedaroglu I. C., Turgut M., Aksu S., et al.50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
  50. Philadelphia-positive acute lymphoblastic leukemia in daily practice: A multicenter experience.Goker H., Tekgunduz E., Sari I., Pala C., Dogu M. H., Ozturk E., et al.49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
  51. Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT.Mohty M., Labopin M., Janssen J. J. W. M., Mufti G. J., Cornelissen J. J., Milpied N., et al.51st Annual Meeting of the American-Society-of-Hematology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Aralık 2009, cilt.114, ss.489, (Özet Bildiri)
  52. Addition of Thalidomide (T) to Oral Melphalan/Prednisone (MP) in Patients with Multiple Myeloma: Initial Results of a Randomized Trial From the Turkish Myeloma Study Group.BEKSAÇ M., HAZNEDAR R., Firatli-Tuglular T., Ozdogu H., Aydogdu I., Konuk N., et al.51st Annual Meeting of the American-Society-of-Hematology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Aralık 2009, cilt.114, ss.746-747, (Özet Bildiri)
  53. Impact of Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)Mohty M., Labopin M., Milpied N., Cornelissen J. J., Blaise D., Petersen E., et al.50th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2008, cilt.112, ss.134-135, (Özet Bildiri)
  54. Haemostatic actions of the folkloric medicinal plant extract, Ankaferd Blood StopperGÖKER H., HAZNEDAROĞLU İ. C., Ercetin S., Kirazli S., Akman U., Ozturk Y., et al.49th Annual Meeting of the American-Society-of-Hematology, Georgia, Amerika Birleşik Devletleri, 8 - 11 Aralık 2007, cilt.110, (Özet Bildiri)
  55. Hematopoetik kök hücre nakli yapılan hastalarda nakil tipine göre yorgunluk düzeyinin karşılaştırılması.YILDIZ KABAK V., DEMİRCİOĞLU KARAGÖZ A., KUMBAROĞLU F. B., ALADAĞ KARAKULAK E., KARAHAN S., GÖKER H., et al.
  56. Proceedings of the World Congress of GastroenterologyBALABAN H. Y., ASLAN A. T., AKDOĞAN KİTTANA F. N., ALP A., DAĞ O., AYAR Ş. N., et al.
  57. Hematopoietic Stem Cell Transplantation for HIV-positive Patients with Hematologic MAlignancies: Three Patients Experience from TurkeyÇiftçiler R., GÖKER H., İNKAYA A. Ç., ÜNAL S., DEMİROĞLU H.
  58. Hepatitis E Virus Epidemiology and Genotype Analysis Among Special Risk Groups in Turkey, 16. Ulusal Hepato Gastroenteroloji Kongresi, 17-23 Ekim 2019-Girne, KKTC.ASLAN A. T., BALABAN H. Y., AYAR Ş. N., AKDOĞAN KİTTANA F. N., ALP A., Vahabov C., et al.
  59. DASATİNİB KULLANIRKEN PLEVRAL EFFÜZYONU GELİŞİP, KÜÇÜK HÜCRELİ AKCİĞER KANSERİ TANISI ALAN BİR OLGUÇİFTÇİLER R., ALADAĞ KARAKULAK E., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., AKSU S., et al.
  60. Laser methods for pharmaceutical pollutants removalSmarandache A., Militaru A., GÖKER H., Pascu A., Pascu M.

All 61 on AVESİS →

Kitaplar 1

  1. Klinik Pratikte HematolojiHAZNEDAROĞLU İ. C., TURGUT M., GÖKER H., BÜYÜKAŞIK Y.nobel tıp kitabevleri, Ankara, 2019

Kontakt

Department
Hematology, Erwachsenenklinik

Zuletzt aktualisiert: